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Reverse cholesterol transportThyroid hormones (THs) exert their actions by binding to thyroid hormone receptors (TRs) and thereby affect
tissue differentiation, development, and metabolism in most tissues. TH-deﬁciency creates a less favorable lipid
proﬁle (e.g. increasedplasma cholesterol levels),whereas TH-excess is associatedwithbothpositive (e.g. reduced
plasma cholesterol levels) and negative (e.g. increased heart rate) effects. TRs are encoded by two genes, THRA
and THRB, which, by alternative splicing, generate several isoforms (e.g. TRα1, TRα2, TRβ1, and TRβ2). TRα, the
major TR in the heart, is crucial for heart rate and for cardiac contractility and relaxation,whereas TRβ1, themajor
TR in the liver, is important for lipid metabolism. Selective modulation of TRβ1 is thus considered as a potential
therapeutic target to treat dyslipidemiawithout cardiac side effects. Several selective THanalogs havebeen tested
in preclinical studieswith promising results, but only a fewof these compounds have so far been tested in clinical
studies. This review focuses on the role of THs, TRs, and selective and non-selective TH analogs in lipid
metabolism. This article is part of a Special Issue entitled: Translating nuclear receptors from health to disease.slating nuclear receptors from
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Cholesterol homeostasis is regulated at levels of synthesis,
absorption, or biliary excretion. Cholesterol and triglycerides (TGs)
are both transported in the blood stream in lipoproteins, a heteroge-
neous group of particles with different lipid and protein compositions
and different sizes. Lipoproteins are traditionally separated into ﬁve
main groups, as follows: chylomicrons, very low density lipoproteins
(VLDL), intermediate density lipoproteins (IDL), low density lipopro-
teins (LDL), and high density lipoproteins (HDL). Each lipoprotein
particle is associated with one or more of the apolipoproteins (apo).
There are three main pathways responsible for the synthesis,
secretion, and transport of lipoproteins within the body: the
exogenous (dietary) pathway, the endogenous (hepatic) pathway,
and reverse cholesterol transport (RCT). Chylomicrons are formed in
the intestine following food intake and contain apoB48 whereas VLDL
are synthesized by the liver and contains apoB100. Chylomicrons and
VLDL acquire apoC and apoE in the circulation. Lipoprotein lipase
hydrolyzes the TG-rich core of chylomicrons and VLDL. The process
results in the formation of chylomicron remnants (CMRs) and VLDL
remnants (also called IDL), respectively, and in the transfer of
phospholipids and free cholesterol to HDL (Fig. 1). The remnantparticles and LDL, formed in the catabolism of VLDL, may be taken up
by the LDL receptor (LDLR) or by the LDLR-related protein (LRP). ApoAI
is the main HDL protein and is a cofactor for lecithin:cholesterol
acyltransferase (LCAT), which esteriﬁes free cholesterol into choles-
teryl esters (CEs). The CE in HDL may be taken up by the liver through
scavenger receptor class B type I (SRBI) or transferred by cholesteryl
ester transfer protein (CETP) to VLDL and LDL, while TG is transferred
in the opposite direction. Originally proposed by Glomset [1], RCT is a
complex process which transfers cholesterol from peripheral cells to
the liver for subsequent elimination in the feces as bile acids and
neutral steroids. Recently, a non-biliary route for cholesterol elimina-
tion from the body has also been described, named trans-intestinal
cholesterol excretion (TICE). TICE is responsible for the direct
transport of cholesterol from blood across the enterocytes into the
intestinal lumen [2]. However, all the different molecular mechanisms
responsible for TICE have not yet been identiﬁed.
Lipoprotein a [Lp(a)] consists of a single apoB100 particle with a
plasminogen-like apo(a) particle attached. Lp(a) is an independent
risk factor for cardiovascular disease [3] and proatherogenic,
prothrombotic, and inﬂammatory pathways are believed to contrib-
ute although the mechanisms are poorly understood [3,4].
Coronary heart disease (CHD) results from the progression of
atherosclerosis and is no longer the principal cause of mortality only
in Western countries (www.who.int). To date, the ﬁrst treatment
choice in the prevention and treatment of CHD are the 3-hydroxy-3-
methylglutaryl–coenzyme A (HMG–CoA) reductase inhibitors, com-
monly known as statins [5]. By lowering the levels of LDL cholesterol,
statins have been able to dramatically reduce CHD in the last two
decades with a 19% reduction in coronary mortality for every 1 mmol/L
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CHD still have a signiﬁcant residual cardiovascular risk despite
aggressive lowering of LDL cholesterol. Since low levels of HDL
cholesterol is an independent risk factor for CHD [7], a potential, and
widely debated, approach is to promote RCT [8].
Thyroid hormones (THs) affect growth, development, and metab-
olism in practically all tissues (reviewed in references 9 and 10).
Particular interest has been given to THs and to TH analogs
(thyromimetics) in relation to their positive effects on lipid and
lipoprotein metabolism, not only because of their ability to lower
plasma total and LDL cholesterol but also due to their ability to
stimulate RCT, at least in preclinical studies [11–14]. However, caution
is required when extrapolating effects of THs on lipid metabolism
from studies in rodents to humans since major differences in the
lipoprotein metabolism exist. In rodents, plasma cholesterol is mainly
transported in HDL, extensive ApoB RNA editing occurs also in the
liver, hepatic lipase circulates in plasma, and rodents lack CETP
activity in plasma. In contrast, LDL is the most abundant lipoprotein in
humans, hepatic lipase is mainly anchored to cell surface—via binding
to heparan sulfate proteoglycans, ApoB RNA editing occurs only in the
intestine, and humans exhibit plasma CETP activity. Moreover, in
contrast to humans, rodents fed with a high-cholesterol diet areFig. 1. Schematic overview of hepatic cholesterol and bile acid metabolism. CE, cholesteryl e
VLDL, very low density lipoprotein; LDL, low density lipoprotein; HDL, high density lipopr
B100; apoE, apolipoprotein E; LCAT, lecithin:cholesterol acyltransferase; LDLR, LDL receptor
G5; ABCG8, ATP-binding cassette transporter G8; ABCB11, ATP-binding cassette transport
acyltransferase 2; HMG–CoA reductase, 3-hydroxy-3-methylglutaryl–coenzyme A reductase
cholesterol transport. Green arrows represent enterohepatic bile acid transport. represresistant to develop hypercholesterolemia [15,16], whereas hormon-
ally deﬁcient rodents on the same diet (e.g. thyroidectomized or
hypophysectomized) do not show this response [17,18].
2. Thyroid hormones and thyroid hormone receptors
2.1. Thyroid hormones and thyroid hormone metabolites
Thyroxine (T4) and triiodothyronine (T3) are synthesized by the
thyroid gland (Fig. 2). T4 is the major secreted hormone and themolar
ratio of serum T4:T3 is ~40. Within the cells, T3 is the transcriptionally
active and more potent TH as it binds to thyroid hormone receptors
(TRs) with 10-fold higher afﬁnity than T4 [10]. The local and systemic
availability of T3 relies on its generation by 5′ deiodination of the outer
ring of T4, a reaction catalyzed by selenoproteins known as
deiodinases (reviewed in references 19 and 20). Different types of
deiodinases exist: type I (D1) are present in peripheral tissues
including the liver; type II (D2) are mainly present in the pituitary
gland, brain, and brown adipose tissue; and type III (D3) are present in
the placenta, brain, and skin. It is generally accepted that D1 and D2
signiﬁcantly contribute to the conversion of T4 into T3 and to the
circulating T3 level in humans and in animals [21]. By extrapolation ofsters; FC, free cholesterol; BA, bile acids; CM, chylomicron; CMR, chylomicron remnant;
otein; apoAI, apolipoprotein AI; apoB48, apolipoprotein B48; apoB100, apolipoprotein
; ABCA1, ATP-binding cassette transporter A1; ABCG5, ATP-binding cassette transporter
er B11; SRBI, scavenger receptor class B type I; ACAT2, acyl-coenzyme A:cholesterol
; CYP7A1, cholesterol 7α-hydroxylase. Blue arrows represent the ﬁnal steps of reverse
ents the positive regulation by TRβ1.
Fig. 2. Simpliﬁed scheme of the synthesis, secretion, and actions of thyroid hormones.
TRH, thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone; T4, thyrox-
ine; T3, triiodothyronine; D, deiodinase; TR, thyroid hormone receptor.
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study has estimated that the D2 activity can be accounted for two
third of the T3 production in humans [22]. D2 deiodinases also
contribute to intracellular levels of T3 and confer to the tissues
expressing this type of deiodinases, the ability to also respond to
circulating T4 without being obligated to circulating T3. D3 deiodi-
nases, together with D1, convert T4 into reverse T3 (rT3). rT3, originally
considered as an inactive metabolite, exerts non-genomic actions on
actin polymerization and microﬁlament organization in astrocytes
and in the cerebellum [9,23]. Sulfatation and glucuronidation
(reviewed in reference 24), which primarily occur in the liver and
to a lesser extent in the kidney, are two other chemical modiﬁcations
leading to inactivation of THs. The resulting metabolites have
increased water solubility that facilitates biliary and urinary secre-
tions. In conditions in which the activity of the D1 deiodinases are low
(e.g. in the fetus), T3 sulphate may serve as a reservoir of inactive T3
from which the active hormone can be generated by the action of
tissue and intestinal bacterial sulphatases [25]. Similarly, iodothyr-
onine glucuronides, once excreted via the bile into the intestine, can
be a substrate for the bacterial β-glucuronidases and the unconju-
gated THs that are generated can be reabsorbed into the body. Thus,
THs undergo enterohepatic recirculation [26].
2.2. Thyroid hormone receptors
In the 1960s, de novo RNA and protein synthesis was reported
upon stimulation by THs [27]. However, the ﬁrst evidence for the
existence of TRs was provided by demonstration of binding of
radiolabeled THs to the same high-afﬁnity, low-capacity sites in the
cellular fraction of intact cells incubated in serum-free medium [28].
Later, identiﬁcation of speciﬁc nuclear binding sites was reported in T3
sensitive organs such as liver, kidney, pituitary, heart, brain, spleen, and
testis [29]. Almost a decade later, two distinct isoforms of TR (TRα and
TRβ) were cloned [30,31] and sequence comparison demonstrated the
TRs as cellular homologs (c-erbA) of a viral oncogene product involved
in avian erythroblastic leukemia (v-erbA). TRs are encoded by the
THRA and THRB genes, located on chromosomes 17 and 3, respectively.
The THRA gene encodes the major TH-binding receptor isoform TRα1
and two non-TH-binding spliced variants (TRα2 and TRα3) [32].
Furthermore, an internal promoter located in intron 7 transcribe the
truncated TRα isoforms (TRΔα1 and TRΔα2), which lack amino-
terminal A/B and DNA-binding domains but retain the majority of the
T3-binding domain [33]. The THRB gene encodes the three TH-binding
isoforms of TRβ (β1, β2, and β3) [34], which share high homology in
the DNA- and T3-binding domains but differ in length and in amino acid
sequences in the amino-terminal A/B domain. An additional variant is
the TRΔβ3 that, compared to TRβ3, lacks the amino A/B domain and the
DNA-binding domain but maintains the T3-binding activity [34]. Both
TRα1 and TRβ1 are expressed in almost all tissues [35]. TRα1 is pre-
dominantly expressed not only in the skeletal muscle and brown
adipose fat but also in the heart, brain, and kidney. TRα2 is pre-
dominantly expressed not only in the placenta and lung but also in the
skeletalmuscle, heart, and kidney. TRβ1 is the predominant TR isoforms
in the liver, brain, and kidney. TRβ2 is expressed in thehypothalamus, in
the anterior pituitary gland, and in the developing brain [35–37].
TRs aremembers of the large superfamily of nuclear receptors (NRs)
and can bind DNA as monomers or homodimers or form heterodimers
mainly with the retinoic-X receptor α (RXRα) (reviewed in references
38–40). TRs are ligand-activated transcription factors and bind both
THs and TH-response elements (TREs), classically located in the
promoter regions of their target genes. TRs have the typical NR
structure. The amino-terminal A/B domains vary among TR isoforms.
The central DNA-binding domain (DBD) is highly conserved and
contains two “zinc ﬁngers” motifs which interact with the nucleotides
of TREs. The ligand-binding domain (LBD) is composed of twelve
amphipathic helices, some of which speciﬁcally interact with co-activators and co-repressors [41–43]. In the absence of THs, TRs bind to
TRE as a heterodimer with RXR and their association to co-repressors
(e.g. NCoR and SMRT) results in repression of the basal transcriptional
activity. Binding of THs to TRs modify the conformation of the LBD
region, a process that involves helix 12 and results in release of co-
repressors and recruitment of co-activators (the steroid receptor co-
activator complex [44] and the vitamin D receptor-interacting protein/
TR associated protein complex [45]). The recruitment of co-activators
modiﬁes the chromatin structures and facilitates the transcriptional
activation. The recruitment of co-activators or co-repressors, depending
upon ligand activation, indicates that animal models, in which TRs
have been genetically depleted, do not necessarily represent condi-
tions with low levels of circulating THs (e.g. after thyroidectomy,
hypophysectomy, or in hypothyroidism). T3was found to regulate N200
genes in the mouse liver [46], but only 60% of these genes showed
dependence on TRβ1, suggesting that TRα1 exerts a more important
function in the liver than commonly believed [46]. Apart from the
genomic effect, which classically are mediated by activation of TRs
bound to the promoter region of the target genes, THsmay also regulate
cells by non-transcriptional pathways (reviewed in reference 47). Non-
transcriptional pathways have been described at the plasma mem-
brane and in various cell organelles and the actions include changes in
solute transport (Na+, Ca2+, and glucose), changes in various kinases
(e.g. PI3K/protein kinase), and regulation of actin polymerization.
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more than 300 families with the syndrome of resistance to TH (RTH),
which are due to mutations in the THRB gene and disturb the TH-
binding, have been identiﬁed. These defects are typically transmitted as
autosomal dominant traits. Overt hypothyroidism, deﬁned as elevated
TSH levels in the presence of decreased free T4 and/or T3 levels, occurs
in ~0.3% of the population and is a major cause of atherosclerotic
disease. Subjects with RTH have greater fat to lean mass, exhibit insulin
resistance, and have elevated levels of circulating free fatty acids and
lower HDL cholesterol levels compared to controls [48].
G protein-coupled bile acid receptor (GPBAR1) or TGR5 is a
recently described receptor, involved in intracellular activation of THs
[49–54]. However, the role and importance of this receptor in lipid
metabolism needs to be further investigated.
3. Thyroid hormones and thyroid hormone analogs
3.1. Preclinical studies investigating the roles of thyroid hormones in
lipid metabolism
Most preclinical data investigating the role of THs in lipid
metabolism are derived from studies in rodent. Chemically induced
hypothyroidism in rats increased plasma total cholesterol, due to
accumulation of apoB-containing lipoproteins and large cholesterol-
enriched HDL, whereas plasma TG-levels were normal or de-
creased. Analysis of hepatic gene expression in these rats showed
increased apoB and decreased LDLR mRNA levels [55–58]. T3-
induced hyperthyroidism in rats did not affect serum cholesterol
levels [55], whereas plasma TG-levels were normal [55] or
increased [59]. In contrast, administration of T3 in mice reduced
plasma total cholesterol levels, mostly due to reduced HDL
cholesterol [11,14]. Plasma TG-levels were normal [14] or decreased
[11]. Thus, thyroid dysfunctions affect lipid metabolism similarly in
rodents as in humans (see below) despite differences in lipid
metabolism (see section 1).
3.2. Hypo- and hyperthyroidism in humans
Hypothyroidism is associated with an increased risk for CHD [60].
Total and LDL cholesterol are commonly increased in hypothyroid
patients [61–63], whereas HDL cholesterol have been reported to be
increased [61,62,64], normal [65], or decreased [66]. In addition,
plasma TG-levels are normal [61] or increased [63,67]. Lipoprotein (a)
[Lp(a)] is a known risk factor for CHD [3,68], and normal [63] or
increased [69] plasma levels have been reported. Hypothyroid
patients excrete less fecal bile acids, neutral sterols, and total steroids
[70]. Intravenous infusion of a fat emulsion, and subsequent
measurement of the turnover rate, has shown that these patients
have lower clearance compared to controls [67,71]. Collectively, these
changes contribute to create a less favorable lipid proﬁle in
hypothyroid patients which may be reversed upon treatment with
synthetic THs.
Hyperthyroidism is also associated with an increased risk for
cardiovascular disease [72,73], but in contrast to hypothyroid
patients, hyperthyroid patients commonly have cardiovascular
signs, which include tachycardia, widened pulse pressure, increased
cardiac output, and impaired cardiovascular and respiratory exercise
capacity [74]. Hyperthyroid patients also commonly have lower
total, LDL, and HDL cholesterol levels [62,63,75]. ApoAI levels are
normal whereas apoB levels are lower [63,75]. Plasma TG-levels
have been reported to be lower [61], normal [67,75], or slightly
elevated [71], whereas Lp(a) levels are lower [69] or normal [63].
Intravenous fat emulsion infusion in hyperthyroid patients, and
subsequent measurement of the turnover rate, showed that these
patients have normal or higher clearance compared to controls
[67,71]. Accordingly, hyperthyroidism is associated with bothpositive (e.g. a less atherogenic lipid and lipoprotein proﬁle) and
negative (e.g. increased heart rate) effects which both may be
restored by treatments with antithyroid medicine, radioactive iodine,
or surgery.
3.3. Initial studies in humans
The ﬁrst human studies, investigating whether THs may lower
plasma cholesterol levels were performed in the 1950s. Eleven
subjects were treated with high doses of dried thyroid (650 mg/
day) for ten weeks which all responded with reduced plasma
cholesterol levels [76]. A long-term study with lower doses was
then initiated in which subjects were treated with 195 mg/day dried
thyroid for thirty weeks [77]. At ﬁrst, the subjects responded with
reduced plasma cholesterol levels, which were maximally lowered
after three weeks, but these were then gradually returned almost to
pre-treatment levels [77]. Another study was then initiated in which
subjects were treatedwith even higher doses of dried thyroid for up to
thirty-nine weeks. However, only thirty-nine of the sixty subjects
completed this study and a large number of the subjects experienced
symptoms of hyperthyroidism (e.g. tachycardia, angina pectoris,
insomnia, and diarrhea) [78].
3.4. Studies on non-selective thyroid hormone analogs in humans
After these initial studies, using dried thyroid, the search for TH
analogs began. A large number of non-selective TH analogs were
investigated in animal models and some of these were also tested in
humans. 3,5,3′-Triiodothyropropionic acid (Triprop), a propionic acid TH
analog, reducedplasmacholesterol levels in small clinical studies [79–81].
3,5-Diiodothyropropionic (DITPA), a carboxylic acid TH analog which
binds with approximately equal afﬁnity to the TRs [82], was tested in
patients with moderately congestive heart failure and improved cardiac
index and signiﬁcantly decreased serum cholesterol and TG-levels [83].
Oxidative deamination anddecarboxylation of the alanine chain of T3 and
T4 form in the liver the acetic acid analogs 3,5,3′-triiodothyroacetic acid
(Triac) and 3,5,3′,5′-tetraiodothyroacetic acid (Tetrac), respectively.
These molecules are metabolically active as demonstrated by the same
efﬁcacy of Tetrac and T4 in patients with myxedema, except for the need
of higher doses [84]. Similarly, the therapeutic doses of Triac are higher
than those needed for T4 to treat thyroid disorders and to reach similar
thyroid-stimulating hormone (TSH) suppression [85]. Interestingly,
plasma total and LDL cholesterol and apoB levels were declined in
the Triac group compared to the T4 group without enhanced
thyromimetic activity speciﬁc to the pituitary gland [85]. The organ-
selective effects of Triac are possibly explained by its higher afﬁnity to
TRβ (3.5-fold) than to TRα (1.5-fold), compared to T3 [86]. However,
treatment with Triac led to increased skeletal turnover [87] and has
therefore not been pursued for the treatment of metabolic diseases.
In “The Coronary Drug Project” [88], men (age, 30–64 years) with
one ormore episodes ofmyocardial infarctionwere recruited to test the
efﬁcacy and safety of several lipid-lowering drugs in the long-term
therapy of CHD. The subjectswere randomized into six groups, of which
one received dextrothyroxine (D-T4, 6.0 mg/day). The study was
terminated after an average follow-up of thirty-six months due to a
higher proportion of deaths in the group receiving the TH analog
compared to the controls, although this was not statistically signiﬁcant.
The results from this study led to the discontinuation of trials with TH
analogs in the 1970s. Later investigations have revealed that the
preparations used in the studywere contaminatedwith ~0.5% L-T4 [89],
which is amorebioactive enantiomer, and theconclusions regarding the
effects ofD-T4may thusnot be correct.Moreover, thedeathsoccurred in
patients already having high cardiovascular risk factors (e.g. angina
pectoris, congestive heart failure, and tachycardia) at the entry of the
study. Exclusion of the high-risk patients showed that the overall
survival in the D-T4-treated groupwas greater than in the controls [90].
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4.1. Lipid-lowering effects by TRβ1 selective thyroid hormone analogs in
preclinical studies
Transgenic expression of dominant-negative mutant TRs and
targeted gene inactivation or knockout of TRs in mice provided
important information on the developmental and physiological
effects of THs [39]. TRα1, TRα2, TRβ1, and TRβ2 have been
successfully ablated in mice, individually or in combination [91–96].
Data from TRα knockout mice showed that T3-induced cardiovascular
liability is mediated by TRα1; deletion of these isoforms resulted in a
slow pulse rate, and administration of T3 could not reverse this effect
[97,98]. Conversely, TRβ1 is the major mediator of the effects of T3 on
cholesterol and lipoprotein metabolism in mice [99]. These ﬁndings
raised the interest in the development of TH analogs that speciﬁcally
can modulate TRβ1, either by selective hepatic uptake and/or by
higher binding afﬁnity to TRβ1 rather than TRα1.
Several TRβ1 selective TH analogs (e.g. SK&F L-94901, GC-1, KB-141,
KB3495, M07811, and T-0681) have been investigated in preclinical
studies (Table 1). SK&F L-94901, which was ﬁrst described, does not
preferentially bind to TRα or TRβ; instead, its selective action results
from the liver speciﬁc uptake [100]. Likewise, the TRβ1 selectivity of
the majority of TH analogs are achieved mainly by liver speciﬁc uptake
rather than by the higher afﬁnity to TRβ1. SK&F L-94901 decreased
plasma cholesterol levels, mainly due to decreased LDL cholesterol in
cholesterol-fed hypothyroid and euthyroid rats [101]. GC-1 (sobetir-
ome) and KB-141 were shown to reduce plasma cholesterol levels in
both euthyroid and hypothyroid mice and rats [11,102–104]. Treat-
ment of cynomolgus monkeys with sobetirome [102] and KB-141
[103] reduced plasma total and LDL cholesterol as well as Lp(a)-levels
and body weight [102,103]. T-0681 decreased plasma apoB-containing
lipoproteins and apoB-mass in cholesterol-fed rabbits [13]. M07811
elicited a similar lipid-lowering effect in rats and in obese mice [105].
Treatment of cynomolgus monkeys with either MB07811 or atorvas-
tatin for seven days decreased serum cholesterol whereas the
combination treatment was associated with signiﬁcantly greater
decreases compared to monotherapy [106]. Importantly, the lipid-
lowering effect was achieved in all the preclinical studies at doses that
did not affect the heart rate; for sobetirome and KB-141, the doses that
produced tachycardia was ~30-fold higher than the therapeutic con-
centrations in rats and even greater in non-human primates [102,103].
Treatment with TRβ1 selective TH analogs also resulted in decreased
plasma TG-levels in several animal models [11,105,107]. KB-141
reduced serum TG-levels in ob–ob [107] but not in diet-induced
obese mice, in which only MB07811 was effective [105]. Sobetirome
reduced plasma TG-levels in hypothyroid [104] and euthyroid mice
[11], and T-0681 decreased plasma TG-levels in hypercholesterolemic
rabbits [13].Table 1
Effects of various selective thyroid hormone analogs on lipid metabolism in different specie
Effect Effects of various selective TH
Rats Mice
Lowering of plasma total and LDL cholesterol levels L-94901 [101] GC-1
GC-1 [104] KB-14
KB-141 [103] M078
M07811 [105] T-068
Lowering of plasma triglyceride levels M07811 [105] GC-1
KB-14
M078
Lowering of plasma lipoprotein(a) [Lp(a)] levels Not applicable Not ap
Reduction of atherosclerotic lesions Not known KB349
T-0684.2. Studies on TRβ1 selective thyroid hormone analogs in humans
Nowadays, pharmacological approaches to selectively stimulate
TRβ1 activity are based on the development of compounds that
interact with the C-terminal LBD and modulates receptor activity.
L-940901, CGH-509A, and CGS23425 are compounds that in animal
studies have been shown to lower serum cholesterol levels without
producing effects on the heart. CGS23425 increased LDLR expres-
sion in HepG2 cells [108], but none of these compounds have been
tested in clinical studies.
At the present time, only a few selective TH mimetic compounds
have been tested in humans (Table 1). QuatRx Pharmaceuticals
obtained the license to sobetirome; the name was changed to QRX-
431 and a phase 1 clinical trial was initiated. In this study, treatment
with QRX-431 for two weeks reduced LDL cholesterol by up to 41%
at doses up to 100 μg and was generally well tolerated by the
euthyroid men [109]. The results have been presented at the 2008
Endocrine Society meeting and are available on the QuatRx Web site
(web reference 110).
KB2115 (eprotirome) is another TRβ1 selective compound that
has been tested in humans [111]. Eprotirome was administrated to
moderately overweight and hypercholesterolemic subjects for two
weeks and was reported to be well tolerated by the subjects with no
serious adverse events, except, for unknown reasons, mild increases
in transaminases. Serum total and LDL cholesterol as well as apoB
levels were reduced without detectable effects on the heart [111]. No
signiﬁcant changes in HDL cholesterol, TG, Lp(a), or body weight were
observed [111]. Bile acid synthesis serves as the major elimination
route of excess cholesterol. In the liver, cholesterol is converted to 7α-
hydroxycholesterol by CYP7A1, the rate-limiting enzyme of the classic
pathway, which is then converted to 7α-hydroxy-4-cholesten-3-one
(C4). Since the classic pathway is responsible for the main part of bile
acid synthesis in humans [112], plasma levels of C4 reﬂects bile acid
synthesis and plasma levels of C4 correlates with the enzymatic
activity of CYP7A1 [113–116]. Plasma levels of C4 were increased at
the higher doses without increased cholesterol production, indicating
that eprotirome induced net cholesterol efﬂux [111].
Eprotirome has also been tested in combination with ezetimibe
and statin therapy. Hypercholesterolemic patients, who were already
treated with ezetimibe, were randomized to receive eprotirome at
three different doses or placebowhile continuing ezetimibe treatment
for ten weeks. Dose-dependent reductions in serum LDL cholesterol,
apoB, TG, and Lp(a) without adverse cardiac or bone effects were
reported. These results have been presented at the American Thyroid
Association Congress on the 26th of September 2009 (web reference
117). Moreover, hypercholesterolemic patients, that were already
treatedwith statins (simvastatin or atorvastatin), were randomized to
treatment with eprotirome or placebo for twelve weeks in addition to
continued statin therapy [118]. The eprotirome-treated patients hads.
analogs on lipid metabolism in different species
Rabbits Monkeys Humans
[11,104] T-0681 [127] GC-1 [102] KB2115 [111,117,118]
1 [105] KB-141 [103] GC-1 [110]
11 [105] MB07811 [119]
1 [127]
[11,104] T-0681 [127] Not known KB2115 [117,118]
1 [107]
11 [105]
MB07811 [119]
plicable Not applicable GC-1 [102] MB07811 [119]
KB-141 [103]
5 [130] T-0681 [127] Not known Not known
1 [127]
Fig. 3. Reverse cholesterol transport and trans-intestinal cholesterol efﬂux pathways.
CE, cholesteryl esters; FC, free cholesterol; TG, triglycerides; VLDL, very low density
lipoprotein; LDL, low density lipoprotein; preβ-HDL, discoidal nascent high density
lipoprotein; HDL, high density lipoprotein; apoAI, apolipoprotein AI; apoB100,
apolipoprotein B100; apoE, apolipoprotein E; CETP, cholesteryl ester transfer protein;
LCAT, lecithin:cholesterol acyltransferase; ABCA1, ATP-binding cassette transporter A1;
ABCG1, ATP-binding cassette transporter G1; SRBI, scavenger receptor class B type I;
ACAT1, acyl-coenzyme A:cholesterol acyltransferase 1. Blue arrows represent the
reverse cholesterol transport. Purple arrows represent trans-intestinal cholesterol
excretion. represents possible positive regulation by TRβ1.
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[118] without adverse effects on heart or bone compared to the
placebo-treated patients. Thus, the reduction of Lp(a) may be a
consequence of the combination therapy with eprotirome and statins
or ezetimibe since administration of eprotirome as monotherapy did
not affect the plasma levels of Lp(a).
In both of the above mentioned studies [111,118], treatment
with eprotirome decreased levels of free and total T4 compared to
placebo but there were no signiﬁcant differences in free and total T3
levels. This indicates that eprotirome acts together with endogenous
TH-levels in the regulation of the hypothalamic–pituitary–thyroid
axis feedback control of peripheral TH homeostasis. Although the
levels remained within the normal ranges, this is something that
needs to be investigated in long-term studies in order to exclude
that a hypothyroid state does not develop in organs that are mainly
dependent on TRα.
MB07811 is another selective THmimetic compound that has been
tested in humans. In a phase 1b clinical trial, dose-dependent
reductions in plasma total and LDL cholesterol, Lp(a), apoB, and TG-
levels were reported in subjects with elevated LDL cholesterol levels
following treatment with MB07811 (web reference 119). In a phase 2
clinical trial (web reference 120), subjects with primary hypercho-
lesterolemia were randomized to placebo or three different doses of
MB07811 for twelve weeks. However, no results from this study have
so far been published.
4.3. Possible mechanisms behind the lipid-lowering effects by selective
thyroid hormone analogs
Recent evidences suggest that the ability of TRβ1 selective TH
analogs to reduce LDL cholesterol can partly be explained by increased
clearance through increased hepatic Ldlr expression. T3 dose-
dependently increased the LDLR promoter activity in cells co-
transfected with TRβ1 [121] and TREs were identiﬁed in the rat Ldlr
promoter [122]. Hypothyroid rats have decreased hepatic Ldlr mRNA
expression [55,56], and reduced receptor-dependent LDL clearance
[58]. Conversely, T3-induced hyperthyroidism, and administration of
T3 to hypophysectomized rats, increased hepatic Ldlr mRNA expres-
sion [55,123]. TRα and TRβ knockout mice have higher Ldlr mRNA
expression compared to hypothyroid mice but the expression did not
increase following T3-administration [124–126]. In addition, treat-
ments with KB-141, MB07811, and T-0681 increased hepatic Ldlr
mRNA expression in several rodent models [13,105,127]. In accor-
dance, Ldlr gene expression was suggested to be crucial for the
thyromimetic effect on lipid metabolism, since LDLR deﬁcient mice do
not respond to treatment with either MB07811 [105] or T-0681 [127].
However, T3 and sobetirome failed to induce hepatic Ldlr mRNA
expression and activity in hypercholesterolemic mice, despite
reduced plasma LDL cholesterol levels [11]. Similarly, T-0681 had no
effect on the hepatic LDLR protein expression, neither in C57BL/6 nor
in apoE deﬁcient mice [127]. Thus, the stimulation of Ldlr expression
by thyromimetic compounds is not an obligate ﬁnding in rodents.
Scavenger receptor class B type I (SRBI) works as an HDL receptor
and mediates selective cholesterol uptake from circulating HDL. To
date, the only data available regarding the modulation of this protein
by TRs come from studies using various TH analogs and suggest that
TRβ1 plays a major role. We have previously shown that neither
sobetirome nor T3 affected hepatic SrbI mRNA levels, whereas the
protein expression was increased in euthyroid mice [11]. When the
micewere fed a high-cholesterol diet, both sobetirome and T3 reduced
hepatic SrbI mRNA levels but only sobetirome (not T3) increased the
protein expression [11].
Cholesterol 7α-hydroxylase (CYP7A1), the rate-limiting enzyme
in the synthesis of bile acids from cholesterol, is a central regulator of
the cholesterol homeostasis. Cyp7a1 mRNA expression and activity
was increased in hypophysectomized rats treatedwith low doses of T3[123,128], and TRβ has been identiﬁed as the primary mediator of
these effects [99,124]. The normal stimulation by T3 on the Cyp7a1
mRNA expression and activity was lost in TRβ but not in TRα1
knockout mice [124]. Importantly, overexpression of TRα1 could not
overcome this defect [99]. Moreover, these studies suggested that TRβ
may exert a negative regulatory effect on lipid metabolism when not
stimulated by THs. T3-deﬁcient TRβ knockout mice showed augmented
Cyp7a1 response after challenge with dietary cholesterol and did not
develop hypercholesterolemia to the same extent as their littermates
[124]. Increased hepatic Cyp7a1 mRNA expression was also reported
in several mouse models following treatment with MB07811, KB-141,
T-0681, or sobetirome [11,105,127]. Plasma levels of C4 reﬂect bile
acid synthesis and correlates with the enzymatic activity of CYP7A1.
Increasedplasma levels of C4,without increased cholesterol production,
were seen in subjects treated with eprotirome for two weeks [111].
Collectively, these results support the hypothesis that eprotirome
increase cholesterol conversion into bile acids rather than by an
upregulation of the LDLR via an increase of the SREBP2 pathway.
ATP-binding cassette transporters (ABCs)G5 andG8mediate, upon
dimerization, biliary cholesterol secretion from the liver. Preclinical
studies suggest a positive regulation of these transporters by TRs,
although different animal models and various selective TH analogs
935C. Pramfalk et al. / Biochimica et Biophysica Acta 1812 (2011) 929–937have generated mixed results. Hepatic Abcg5 and Abcg8 mRNA
expression was almost completely repressed in hypophysectomized
rats, whereas T4 administration increased their expression [129]. This
effect was coupled to increased hepatic secretion of cholesterol [129],
which is in line with the observed increased hepatic Abcg5 and Abcg8
mRNA expression in hyperthyroid mice [14]. Treatment with T-0681
increased hepatic Abcg5 and Abcg8mRNA expression in C57BL/6, SRBI
knockout, and LDLR knockout mice, but not in CETP transgenic mice
[127]. We have recently observed that treatment of apoE deﬁcient
mice with the new thyromimetic compound KB3495 (Karo Bio AB) for
twenty-ﬁve weeks increased neutral sterol excretion whereas the
hepatic Abcg5 and Abcg8mRNA expression was not affected [130].
4.4. TRβ1 selective thyroid hormone analogs as potential therapeutic
compounds
As described in section 1, statins are effective in lowering hepatic
cholesterol levels, yet high-risk patients experience further events of
CHD. Thus, there is still a need for novel pharmacological strategies,
and treatments targeted to promote cholesterol excretion from the
bodymay be potential candidates. Two pathways have been shown to
mediate cholesterol excretion in mice: RCT [8], which is a biliary-
dependent route, and TICE,which is a non-biliary route [2] (Fig. 3). RCT
can be summarized in four major steps, as follows: i) synthesis and
lipidation of apoAI to generate nascent HDL; ii) efﬂux of excess
cholesterol from peripheral cells (e.g. macrophages) to plasma HDL;
iii) hepatic uptake of cholesterol fromHDL via SRBI and LDL via LDLR—
the latter especially in the presence of CETP; and iv) biliary secretion of
cholesterol, as such or after its conversion to bile acids, for ﬁnal
excretion from body in the feces. As mentioned in section 1, studies in
rodents strongly suggest that TRβ1 can positively affect lipid
metabolism by up-regulating genes involved in the last steps of RCT.
A further conﬁrmation of this hypothesis has recently been provided
by a direct quantiﬁcation of the in vivoRCT [131] inmice treatedwith T-
0681 [127]. T-0681 was shown to stimulate the in vivo RCT in C57BL/6
mice resulting in elevated fecal excretion of radiolabeled cholesterol,
bothasneutral sterols and asbile acids, but T-0681 failed to increaseRCT
in CETP transgenicmice [127]. Moreover, we recently observed a strong
increase in fecal neutral sterol excretion in apoE deﬁcient mice treated
with KB3495, despite no major effects on the hepatic Abcg5 and Abcg8
mRNA expression [130]. This suggests that TRβ1 modulation may also
promote cholesterol excretion by stimulating TICE [2]. Further studies
are required in order to clarify the link between TRβ1 and lipidmetabo-
lism through RCT and TICE.
5. Conclusions
Today, statins are used as the ﬁrst treatment choice to lower
plasma total and LDL cholesterol levels, but high-risk patients still
experience further events of CHD. Thus, there is a need for novel
pharmacological strategies. Preclinical and clinical studies using
selective TH analogs are promising and suggest TRβ1 as a potential
target for treatment of dyslipidemia. Of particular interest are the
ﬁndings of reduced plasma levels of Lp(a) following combination
therapy with eprotirome and statins or ezetimibe, since only a few
drugs so far have been shown to have any effect on these levels. As
shown in preclinical studies, TRβ1 modulation may also promote
cholesterol excretion by stimulating RCT and TICE [2], which needs to
be investigated also in humans. However, so far, studies performed in
humans are limited and the positive and negative long-time effects of
TRβ1 modulation are still unknown.
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